2.1. Subjects

Two hundred age- and sex-matched subjects including 100 healthy individuals and 100 MS patients referred to Peymanieh Hospital (Jahrom city, Iran) were recruited in the study (from November 2018 to February 2020). Patients whose diseases were approved by a neurologist were divided into secondary-progressive (SP), primary-progressive (PP), and relapsing-remitting (RR) subtypes. Patients and healthy subjects with a history of any inflammatory diseases, autoimmune diseases, cancer, and neurological diseases were excluded from the study. Also, healthy people who had autoimmune disease in their first degree relatives were excluded from the study. Methylprednisolone, plasmapheresis and intravenous immunoglobulin (IV-IG) were used to treat patients in the acute and symptomatic stage of the disease. After treatment, IFNβ-1b, IFNβ-1a, Glatiramer acetate, Fingolimod and dimethylformamid drugs were used in order of priority for maintenance and prevention of relapsing multiple sclerosis. For the treatment of relapsing-remitting multiple sclerosis (RRMS) Rituximab (anti-CD20), Ocrelizumab (anti-CD20) and Natalizumab were used.